Andy Keil
About Andy Keil
Andy Keil serves as the Head of Product at QuotaPath and has extensive experience in product management and development across various companies. He has also worked as an advisor, investor, and game designer, contributing to multiple projects in the Austin, Texas area.
Current Role at QuotaPath
Andy Keil serves as the Head of Product at QuotaPath since 2023. In this role, he is responsible for overseeing product strategy and development. His leadership focuses on enhancing user experience and driving product innovation within the company. QuotaPath is known for its commission tracking software, and under Keil's guidance, the product team aims to streamline processes for users.
Previous Experience at QuotaPath
Before his current position, Andy Keil held multiple roles at QuotaPath. He worked as the Director of Product from 2021 to 2022 and as the Sr. Director of Product from 2022 to 2023. During his tenure, he contributed to various product initiatives and improvements, helping to shape the direction of the company's offerings.
Professional Background
Andy Keil has a diverse professional background in product management and consulting. He has held positions at several companies, including Phobio as Sr. Product Manager and Digital Pharmacist Inc. as Sr. Product Manager. Additionally, he served as Head of Product & Strategy at DocStation and was involved with Techstars as Director of Startup Next. His experience spans various industries, emphasizing product development and strategy.
Education and Skills
Andy Keil studied at Columbia College of Chicago, where he earned a Bachelor's degree in Audio Arts & Acoustics, Music Business, Journalism, and Photography from 2008 to 2011. He also attended Iowa State University for Computer Science from 2007 to 2008. His educational background supports his skills in product management, user experience design, and marketing.
Advisory and Investment Roles
In addition to his role at QuotaPath, Andy Keil is currently an Advisor at OpenCourt, a position he has held since 2024. He is also a Limited Partner at Stage 2 Capital Catalyst since 2022 and serves as an Angel Investor at MedScout since 2021. These roles highlight his involvement in the startup ecosystem and his commitment to supporting emerging companies.